{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:49:18Z","timestamp":1783662558629,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcf.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T19:38:41Z","timestamp":1687635521000},"page":"847-850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF"],"prefix":"10.1016","volume":"22","author":[{"given":"David","family":"Proud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcf.2023.06.002_bib0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcf.2023.06.002_bib0002","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jcf.2022.08.004","article-title":"Time to change course and tackle CF related obesity","volume":"21","author":"Caley","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.002_bib0003","series-title":"Cystic fibrosis foundation patient registry 2021 annual data report","year":"2022"},{"key":"10.1016\/j.jcf.2023.06.002_bib0004","series-title":"UK Cystic fibrosis registry 2021 annual data report","year":"2022"},{"key":"10.1016\/j.jcf.2023.06.002_bib0005","year":"2017","journal-title":"The Canadian cystic fibrosis registry 2016 annual data report"},{"key":"10.1016\/j.jcf.2023.06.002_bib0006","series-title":"The Canadian cystic fibrosis registry 2021 annual data report","year":"2023"},{"issue":"9","key":"10.1016\/j.jcf.2023.06.002_bib0007","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jcf.2023.06.002_bib0008","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2021.11.008","article-title":"Forewarned is forearmed: the cardiovascular time bomb in Cystic Fibrosis","volume":"21","author":"Duckers","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.002_bib0009","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.jcf.2023.06.002_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jbspin.2015.04.021","article-title":"Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis","volume":"83","author":"Baker","year":"2016","journal-title":"Jt Bone Spine"},{"issue":"5","key":"10.1016\/j.jcf.2023.06.002_bib0011","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcf.2021.06.004","article-title":"The association between body composition, leptin levels and glucose dysregulation in youth with cystic fibrosis","volume":"20","author":"Granados","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.06.002_bib0012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clnu.2015.03.001","article-title":"Diagnostic criteria for malnutrition - an ESPEN Consensus Statement","volume":"34","author":"Cederholm","year":"2015","journal-title":"Clin Nutr"},{"issue":"10212","key":"10.1016\/j.jcf.2023.06.002_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the Elexacaftor\/Tezacaftor\/Ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.06.002_bib0014","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in patients with Cystic Fibrosis and one or two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.06.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2020.111124","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"key":"10.1016\/j.jcf.2023.06.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2023.06.002_bib0018","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1569-1993(22)00166-7","article-title":"Understanding beliefs about Elexacaftor\/tezacaftor\/ivacaftor (ETI) therapy in adults living with cystic fibrosis","volume":"21","author":"O'Leary","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:17:35Z","timestamp":1756714655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1569199323001807"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.06.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}